Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;33(9):e5862.
doi: 10.1002/pds.5862.

Contemporary Practice and Considerations for Real-World Data Source Identification and Feasibility Assessment

Dony Patel  1 , Sonia Guleria  2 , Lina Titievsky  3 , Susanna Flaherty  4 , Nicholas Everage  5 , Marta Korjagina  6 , Sheuli Porkess  7   8 , Tzuyung Douglas Kou  9 , Deborah Layton  10   11
Affiliations

Contemporary Practice and Considerations for Real-World Data Source Identification and Feasibility Assessment

Dony Patel et al. Pharmacoepidemiol Drug Saf. 2024 Sep.

Abstract

Purpose: There has been rapid growth in the variety and number of real-world data (RWD) sources, as well as the number of regulatory documents that provide guidance for assessing the suitability of RWD sources for pharmacoepidemiology studies. This study aims to assess differences in RWD guidance and variability in current practice for identifying and assessing RWD for studies with regulatory purpose.

Methods: Key criteria for feasibility assessment were mapped against relevant regulatory guidance documents across US, EU, and Asia-Pacific regions. An online survey was designed and deployed to International Society for Pharmacoepidemiology members to understand current practice. Findings were summarized and used to inform key considerations and recommendations.

Results: Eleven RWD guidance documents were identified and mapped against 14 RWD assessment criteria. Variability was seen across these documents in guidance for these criteria. Between December 2022 and January 2023, 37 survey respondents reported having used RWD for post-marketing commitments (34, 92%) and/or background epidemiology (28, 76%). RWD were mostly identified through literature (33, 89%) and data landscaping (26, 70%); guidance documents referenced included: Food and Drug Administration (20, 54%), European Network for Centres for Pharmacoepidemiology and Pharmacovigilance (17, 46%), European Medical Agency (16, 43%), and Structured Process to Identify Fit-For-Purpose Data (11, 30%). Challenges for conducting feasibility assessments included RWD accessibility, ability to complete validation, and RWD provider responsiveness.

Conclusions: Existing guidelines are used extensively by researchers, but key criteria for RWD identification and feasibility assessment are not reflected consistently and challenges remain. Recommendations have been made reflecting study findings.

Keywords: feasibility; fit‐for‐purpose; real‐world data; real‐world evidence.

PubMed Disclaimer

References

    1. U.S. Food & Drug Administration, “Real‐World Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision‐Making for Drug and Biological Products, Draft Guidance for Industry,” 2021.
    1. International Council for Harmonisation (ICH), “International Harmonisation of Real‐World Evidence Terminology and Convergence of General Principles Regarding Planning and Reporting of Studies Using Real‐World Data, With a Focus on Effectiveness of Medicines,” 2023, https://admin.ich.org/sites/default/files/2023‐06/ICH_ReflectionPaper_Ha....
    1. A. Makady, A. de Boer, H. Hillege, O. Klungel, and W. Goettsch, “What Is Real‐World Data? A Review of Definitions Based on Literature and Stakeholder Interviews,” Value in Health 20, no. 7 (2017): 858–865.
    1. J. M. Franklin, R. J. Glynn, D. Martin, and S. Schneeweiss, “Evaluating the use of Nonrandomized Real‐World Data Analyses for Regulatory Decision Making,” Clinical Pharmacology & Therapeutics 105, no. 4 (2019): 867–877.
    1. US FDA, “Considerations for the Use of Real‐World Data and Real‐World Evidence to Support Regulatory Decision‐Making for Drug and Biological Products,” 2023, https://www.fda.gov/regulatory‐information/search‐fda‐guidance‐documents....

Publication types

Grants and funding

LinkOut - more resources